28th Apr 2014 12:28
LONDON (Alliance News) - GlaxoSmithKline PLC and Theravance Inc Monday launched their chronic obstructive pulmonary disease treatment Anoro Ellipta at retail pharmacies in the US.
Under the terms of its agreement with Glaxo, Theravance has agreed to make a milestone payment of USD30 million to Glaxo following the US launch of the product.
?We understand that COPD is a progressive disease affecting an estimated 27 million people in the US alone,? said Senior Vice President of Glaxo's Respiratory Business in the US Jorge Bartolome. ?Anoro Ellipta is an important treatment option for appropriate patients with COPD, and we are proud to make it available in the US.?
Glaxo also announced Monday that, in conjunction with Medicines for Malaria Venture, it will be beginning a Phase III programme to evaluate tafenoquine for the treatment and relapse prevention of Plasmodium vivax malaria.
The Phase III programme will investigate the efficacy and safety of the treatment in two double-blind treatment studies.
Shares in Glaxo were trading up 0.6% at 1,665.50 pence Monday. It will announce its first quarter results Wednesday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline